Teva Pharmaceutical Industries (TEVA) Earnings: Q3 2026 Results and Next Report Date

The quarter ended September 30, 2026 and Teva Pharmaceutical Industries published the results on November 3, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Teva Pharmaceutical Industries reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Since January 1, 2026 Teva reports its Anda distribution business under Other Activities, not the United States segment, and has recast prior periods. The year-ago Other Activities figure is from Teva's Form 10-Q.
• Teva's Q3 2026 GAAP results include $228 million of long-lived asset impairments, $201 million of legal settlements and loss contingencies and a $224 million loss on extinguishment of debt from refinancing, all excluded from non-GAAP EPS.

Source: Teva Q3 2026 results, November 3, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Teva Pharmaceutical Industries splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Teva Pharmaceutical Industries's United States revenue was $1.9 billion in Q3 2026, down 11% from $2.1 billion in Q3 2025, 43% of total revenue.
• Teva Pharmaceutical Industries's Europe revenue was $1.3 billion in Q3 2026, up 7% from $1.2 billion in Q3 2025, 30% of total revenue.
• Teva Pharmaceutical Industries's International Markets revenue was $592 million in Q3 2026, up 6% from $557 million in Q3 2025, 13% of total revenue.
• Teva Pharmaceutical Industries's Other Activities revenue was $613 million in Q3 2026, up 3% from $598 million in Q3 2025, 14% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Teva's release sets its 2026 outlook as ranges in a table: revenues of $16.7 billion to $17.0 billion (previously $16.5 billion to $16.85 billion), non-GAAP operating income of $3.8 billion to $3.9 billion, Adjusted EBITDA of $4.23 billion to $4.43 billion, non-GAAP diluted EPS of $1.92 to $2.11 (including $0.71 of acquired IPR&D charges) and free cash flow of $2.1 billion to $2.4 billion. It raised its AUSTEDO revenue outlook to $2.55 billion to $2.65 billion, AJOVY to $930 million to $960 million and UZEDY to $290 million to $310 million.

In its Q3 2026 release, Teva Pharmaceutical Industries said:

“Considering the above, we expect our annual non-GAAP tax rate for 2026 to be between 20%-23%, higher than our non-GAAP tax rate for 2025, which was 15.8%.”

“Teva currently expects more than $0.8 billion in biosimilars revenues in 2026, reaching its original 2027 revenue objective one year early, with further portfolio expansion supported by new collaborations, including the recently announced agreement with Samsung Bioepis.”

“Financial guidance only assumes business development transactions closed as of November 3, 2026.”

Source: Teva Q3 2026 release, Nov 3, 2026.

This is the company's own guidance as of Nov 3, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the TEVA forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net revenues and diluted EPS attributable to Teva, each as first reported in that quarter's release.

Teva Pharmaceutical Industries's next report is expected around January 27, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q3 2026 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 3, 2026

Teva Pharmaceutical Industries reported Q3 2026 net revenues of $4,395 million, down 2% from $4,480 million. The United States segment brought in $1,870 million, Europe $1,319 million, International Markets $592 million and Other Activities, mainly the Anda distribution business, $613 million. (Teva Q3 2026 earnings release, Nov 3, 2026; Teva Form 10-Q, Q3 2026, Nov 3, 2026)

Teva's three key innovative brands generated about $1.1 billion, up 33% in local currency. AUSTEDO global revenues were $751 million, up 21%, AJOVY $269 million, up 61%, and UZEDY $85 million, up 96%. In the U.S., AUSTEDO revenues of $727 million grew on volume and a favorable business mix including improved net-price realization. (Teva Q3 2026 earnings release, Nov 3, 2026)

U.S. generic products (including biosimilars) fell 39% to $718 million, mainly on lower revenues from lenalidomide capsules, a generic version of Revlimid, after increased competition. Global generics revenues fell 16% in local currency. Teva's trailing twelve-month U.S. generic prescriptions were about 227 million, 5.8% of the total, against 6.7% a year earlier. (Teva Q3 2026 earnings release, Nov 3, 2026)

Europe revenues rose 7% on higher generic revenues, sales of certain product rights and AJOVY, and International Markets rose 6%. Teva's 2025 Form 10-K lists McKesson Corporation at 13% and AmerisourceBergen Corporation at 11% of 2025 third-party net sales, mostly in the United States segment. (Teva Q3 2026 earnings release, Nov 3, 2026; Teva Form 10-K, 2025, Feb 3, 2026)

Teva's GAAP diluted EPS fell to $0.20 from $0.37 while non-GAAP diluted EPS rose to $0.86 from $0.78. Non-GAAP adjustments totaled $780 million, including $228 million of impairment of long-lived assets, $201 million of legal settlements and loss contingencies, $139 million of amortization of purchased intangible assets, $58 million of restructuring and $235 million of financial expenses. (Teva Q3 2026 earnings release, Nov 3, 2026)

Financial expenses, net were $414 million, including a $224 million loss on extinguishment of debt after Teva redeemed $4,678 million of senior notes early and issued $4,837 million of new notes. Teva's GAAP tax rate was 22.1% against 33.1% and its non-GAAP tax rate 16.5% against 14.7%. (Teva Q3 2026 earnings release, Nov 3, 2026)

Gross profit margin widened to 55.5% from 51.4%, and non-GAAP gross margin to 58.7%, which Teva attributes to a mix shift toward its innovative products, largely AUSTEDO. Diluted weighted average shares were 1,183 million against 1,164 million. (Teva Q3 2026 earnings release, Nov 3, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Teva Pharmaceutical Industries raised parts of its 2026 outlook with Q3 results. Revenues are now expected at $16.7 billion to $17.0 billion, up from $16.5 billion to $16.85 billion, and non-GAAP diluted EPS at $1.92 to $2.11, including $0.71 of acquired IPR&D charges. The AUSTEDO revenue range rose to $2.55 billion to $2.65 billion and AJOVY to $930 million to $960 million. (Teva Q3 2026 earnings release, Nov 3, 2026)

Teva expects a 2026 non-GAAP tax rate of 20%-23%, against 15.8% in 2025, and more than $0.8 billion of biosimilars revenues in 2026. It continues to target a 30% non-GAAP operating income margin and about $700 million of net savings by 2027. (Teva Q3 2026 earnings release, Nov 3, 2026)

A consensus figure is the average of the models published by the analysts who cover Teva Pharmaceutical Industries, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Teva Pharmaceutical Industries's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning TEVA is on is TEVA a buy or a sell?, what analysts expect next is on the TEVA forecast, and what the company does is on the Teva Pharmaceutical Industries (TEVA) stock page.

Every number on this page can be traced to a document Teva Pharmaceutical Industries published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.